Dupilumab Approved for Eczema for Children 6 Months to 5 Years Dupilumab Approved for Eczema for Children 6 Months to 5 Years
The approval makes dupilumab the first biologic available in the United States to treat uncontrolled moderate-to-severe atopic dermatitis in this age group.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Dermatology News Source Type: news
More News: Allergy | Allergy & Immunology | Children | Dermatitis | Dermatology | Eczema | Skin | USA Health